LLY

1,049.5

+0.26%↑

JNJ

243.8

-0.1%↓

ABBV

232.27

+2.94%↑

NVS

163.09

+1.14%↑

MRK

122.07

+1.64%↑

LLY

1,049.5

+0.26%↑

JNJ

243.8

-0.1%↓

ABBV

232.27

+2.94%↑

NVS

163.09

+1.14%↑

MRK

122.07

+1.64%↑

LLY

1,049.5

+0.26%↑

JNJ

243.8

-0.1%↓

ABBV

232.27

+2.94%↑

NVS

163.09

+1.14%↑

MRK

122.07

+1.64%↑

LLY

1,049.5

+0.26%↑

JNJ

243.8

-0.1%↓

ABBV

232.27

+2.94%↑

NVS

163.09

+1.14%↑

MRK

122.07

+1.64%↑

LLY

1,049.5

+0.26%↑

JNJ

243.8

-0.1%↓

ABBV

232.27

+2.94%↑

NVS

163.09

+1.14%↑

MRK

122.07

+1.64%↑

Search

Emergent BioSolutions Inc

Open

BrancheGesundheitswesen

11.06 2.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.65

Max

11.22

Schlüsselkennzahlen

By Trading Economics

Einkommen

63M

51M

Verkäufe

90M

231M

KGV

Branchendurchschnitt

8.293

121.746

Gewinnspanne

22.155

Angestellte

900

EBITDA

95M

96M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+35.99% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

26. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

69M

588M

Vorheriger Eröffnungskurs

8.18

Vorheriger Schlusskurs

11.06

Nachrichtenstimmung

By Acuity

67%

33%

313 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Emergent BioSolutions Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Feb. 2026, 23:57 UTC

Heiße Aktien

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12. Feb. 2026, 23:35 UTC

Ergebnisse
Wichtige Markttreiber

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12. Feb. 2026, 23:28 UTC

Ergebnisse

Applied Materials Profit Rises on Soaring AI Demand -- Update

12. Feb. 2026, 21:47 UTC

Ergebnisse

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13. Feb. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12. Feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12. Feb. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12. Feb. 2026, 23:33 UTC

Ergebnisse

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12. Feb. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12. Feb. 2026, 22:55 UTC

Ergebnisse
Heiße Aktien

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12. Feb. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12. Feb. 2026, 22:23 UTC

Ergebnisse

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12. Feb. 2026, 22:15 UTC

Ergebnisse

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12. Feb. 2026, 22:00 UTC

Ergebnisse

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. Feb. 2026, 22:00 UTC

Ergebnisse

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12. Feb. 2026, 21:57 UTC

Ergebnisse

XP 4Q Rev BRL4.95B >XP

12. Feb. 2026, 21:52 UTC

Ergebnisse

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. Feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Feb. 2026, 21:47 UTC

Ergebnisse

Morningstar 4Q Rev $641M >MORN

12. Feb. 2026, 21:39 UTC

Ergebnisse

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. Feb. 2026, 21:38 UTC

Ergebnisse

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Peer-Vergleich

Kursveränderung

Emergent BioSolutions Inc Prognose

Kursziel

By TipRanks

35.99% Vorteil

12-Monats-Prognose

Durchschnitt 15 USD  35.99%

Hoch 15 USD

Tief 15 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Emergent BioSolutions Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

4.95 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

313 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat